Gilead's Covid-19 drug may get quick FDA approval

This post was originally published on this site

Gilead’s (NASDAQ:GILD) treatment for coronavirus “could be approved for Covid-19 very soon,” a Piper Sandler analyst says.

“We now believe the remdesivir clinical trial results are likely to be positive,” analyst Tyler Van Buren says of GILD’s experimental medicine.

“If successful, it could be approved for broad use in the coming months considering it’s safe, the bar for efficacy in the context of the ongoing global pandemic is low.”

GILD +9.4% today.

Source: dailystockbuzz

Leave a comment

Your email address will not be published. Required fields are marked *